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C A N C E R
ACSL3–PAI-1 signaling axis mediates tumor-stroma 
cross-talk promoting pancreatic cancer progression
Matteo Rossi Sebastiano1, Chiara Pozzato1, Maria Saliakoura1, Zhang Yang2,  
Ren-Wang Peng2, Mirco Galiè3, Kevin Oberson1, Hans-Uwe Simon1,4,  
Evanthia Karamitopoulou5, Georgia Konstantinidou1*
Pancreatic ductal adenocarcinoma (PDAC) is characterized by marked fibrosis and low immunogenicity, features 
that are linked to treatment resistance and poor clinical outcomes. Therefore, understanding how PDAC regulates 
the desmoplastic and immune stromal components is of great clinical importance. We found that acyl-CoA 
synthetase long-chain 3 (ACSL3) is up-regulated in PDAC and correlates with increased fibrosis. Our in vivo results 
show that Acsl3 knockout hinders PDAC progression, markedly reduces tumor fibrosis and tumor-infiltrating 
immunosuppressive cells, and increases cytotoxic T cell infiltration. This effect is, at least in part, due to decreased 
plasminogen activator inhibitor–1 (PAI-1) secretion from tumor cells. Accordingly, PAI-1 expression in PDAC 
positively correlates with markers of fibrosis and immunosuppression and predicts poor patient survival. We 
found that PAI-1 pharmacological inhibition strongly enhances chemo- and immunotherapeutic response against 
PDAC, increasing survival of mice. Thus, our results unveil ACSL3–PAI-1 signaling as a requirement for PDAC 
progression with druggable attributes.
INTRODUCTION
Pancreatic ductal adenocarcinoma (PDAC) represents 95% of all 
pancreatic cancers and, with a 5-year survival rate of only 7%, is one 
of the deadliest malignancies (1). Surgery remains the only yet in-
sufficient approach for the treatment of PDAC, as this carcinoma is 
highly refractory to all available antitumor pharmacological options 
(2). This is, at least in part, due to the strong desmoplastic reaction 
associated with PDAC progression, displaying a strong activation of 
pancreatic stellate cells (PSCs) and formation of dense extracellular 
matrix that causes insufficient tumor perfusion and acts as an 
impenetrable barrier to intravenously injected anticancer molecules 
or chemotherapeutic agents (3). Moreover, tumor-associated macro-
phages (TAMs) including M2-like macrophages (or alternatively 
activated macrophages) promote fibrosis and inhibit both adaptive 
and innate antitumor immunity by secreting immunosuppres-
sive molecules including transforming growth factor– (TGF-), 
interleukin-10 (IL-10), and arginase 1 (Arg1), thus negatively 
affecting patient outcomes (4, 5). Therefore, a better understanding 
of the biology of PDAC, including the mechanisms linking its pro-
gression with the regulation of its stromal components, is urgent, as 
it will provide insights that can be translated into needful therapeu-
tic strategies.
The most common gene alterations in human PDACs include 
mutations in the KRAS oncogene (95% of cases) and inactivating 
mutations in the TP53 tumor suppressor (75% of cases) (6). Mouse 
models have recapitulated this observation, where Kras activation 
in combination with a point mutation or deletion of one copy of the 
Trp53 gene is sufficient to induce PDAC with characteristic features 
of the human disease, including progression from preinvasive pan-
creatic intraepithelial neoplasia lesions (PanINs) to invasive PDACs 
and strong association with desmoplastic stroma (7–9). Hence, 
these genetically engineered mouse models provide a unique op-
portunity to interrogate the functional molecular requirements for 
PDAC progression and to define features such as the desmoplastic 
stromal reaction.
We previously found that the acyl–coenzyme A (CoA) synthetase 
long-chain family member 3 (ACSL3) is necessary for the extra-
cellular lipid utilization and proliferation of KRAS-driven cancer 
cells because of its role in activation of extracellularly derived long-
chain fatty acids (10). The proliferation of PDAC strongly depends 
on extracellularly derived fatty acids, including lipids derived from 
stromal components, such as PSCs (11, 12). Thus, we hypothesized 
that ACSL3 is a crucial requirement for this malignancy and that 
studying the functional effect of ACSL3 suppression will unmask 
important requirements of PDAC that could be therapeutically 
exploited. Here, by using genetically defined KrasG12D-driven 
pancreatic cancer mouse models, human pancreatic ductal epithelial 
(HPDE) cell lines, human patient samples, and epidemiological data, 
we interrogated the role of ACSL3 signaling in PDAC progression 
to uncover an underlying tumorigenic mechanism with druggable 
attributes.
RESULTS
ACSL3 is up-regulated in human PDAC
To assess the expression level of ACSL3 in human pancreatic 
cancer, we examined publicly available human patient-derived 
data from the Gene Expression Omnibus (GEO) database (subset 
GSE71729). Our analysis evidenced that the mRNA level of ACSL3 
is higher in primary ductal adenocarcinomas and metastasis com-
pared to healthy epithelium (Fig. 1A). These results were addition-
ally confirmed with paired analysis from matched healthy and 
PDAC human samples (dataset GSE62452), showing a marked in-
crease in the expression of ACSL3 compared to adjacent healthy 
tissue from the same patients (Fig. 1B).
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Next, we performed immunohistochemistry (IHC) for ACSL3 on 
a tissue microarray (TMA) containing 50 PDAC patient samples. 
We scored for low, intermediate, or high ACSL3 protein levels 
based on a histological score that takes into consideration the per-
centage of cells stained at different intensities (H-score). We found 
that ACSL3 was barely detectable in the normal pancreatic epithelium, 
modestly expressed in PanINs, and markedly elevated in PDAC 
(Fig. 1, C and D, and fig. S1A). Notably, we found that a high ACSL3 
H-score positively correlates with a higher tumor histological grade 
(Fig. 1E). Next, to confirm the above results, we used matched 
healthy and PDAC tissue from five pancreatic cancer patients, and 
we assessed ACSL3 protein levels by immunoblot analysis. This 
analysis evidenced a consistent increase of ACSL3 protein in PDAC 
compared to healthy tissue (Fig. 1F).
To determine whether high levels of ACSL3 in PDAC cells 
correlate with elevated stromal fibrosis, we stratified human PDAC 
patient samples on the basis of low, intermediate, or high ACSL3 
H-score and assessed the degree of collagen deposition by Masson 
trichrome staining. Notably, this analysis evidenced that high ACSL3 
protein levels are associated with a higher degree of fibrosis 
(Fig. 1, C and G, and fig. S1B). Together, the data strongly suggest 
a positive role of ACSL3 in PDAC progression and desmoplastic 
stromal reaction.
Acsl3 deletion delays PDAC progression and reduces fibrosis 
in mice
To assess the impact of Acsl3 deletion on PDAC progression in a 
genetically defined mouse model, we generated mice carrying a 
transgene, allowing tamoxifen-dependent expression of the Cre 
recombinase under the pancreas-specific Pdx-1 promoter (Pdx1-
CreERT2), a Cre-activatable KrasG12D allele (LSL-KrasG12D/+), homo-
zygous for a Cre-conditional p53 knockout allele (p53floxflox), and 
either wild type or homozygous for an Acsl3 knockout allele (Acsl3+/+ 
or Acsl3−/−, respectively), to generate two experimental groups: 
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Fig. 1. ACSL3 is overexpressed in human PDAC. (A) mRNA levels of ACSL3 in patient healthy tissue, primary PDAC, and PDAC metastasis from the subset GSE71729. 
Healthy pancreatic tissue: n = 46 patients, primary PDAC: n = 145 patients, and PDAC metastasis: n = 61 patients. Data are represented as box (Whisker’s) plot. Dots evi-
dence outliers according to Tukey’s method. (B) mRNA levels of ACSL3 in patient primary PDAC and matched adjacent healthy tissue from the subset GSE62452 (n = 60). 
Data are expressed as entire numbers normalized by global average. (C) Representative IHC staining for ACSL3 (top) and extracellular matrix deposition marker with 
Masson trichrome (blue, bottom) of a human TMA showing primary healthy tissue, PanIN, and primary PDAC. Scale bars, 50 μm. (D) ACSL3 IHC quantification (H-score) of 
TMA comparing PDAC and adjacent healthy tissue (n = 50 samples). We considered an H-score of less than 100, from 100 to 200, and above 201 having a low, intermedi-
ate, or high staining intensity, respectively. (E) Stratification of the patients by tumor grade from (D). Healthy tissue, n = 50 samples; grade I, n = 5 samples; grade II, 
n = 23 samples; grade III, n = 22 samples. (F) Immunoblot for ACSL3, total RAS, and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) of five human patient-derived tu-
mor samples and matched adjacent healthy tissue. (G) Correlation between ACSL3 and Masson trichrome staining of TMA from (C) and (D). Samples are divided in low, 
intermediate, and high ACSL3 staining. We considered an H-score of less than 100, from 100 to 200, and above 201 having a low, intermediate, or high staining intensity, 
respectively. Error bars represent mean ± SD; statistical analysis was performed using one-way ANOVA. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001.
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LSL-KrasG12D/+;p53flox/flox;Pdx1-CreERT2;Acsl3+/+ and LSL-KrasG12D/+; 
p53flox/flox;Pdx1-CreERT2;Acsl3−/− (hereafter named KPC;Acsl3+/+ and 
KPC;Acsl3−/−, respectively). Tamoxifen injection to these mice drives 
the Cre-mediated recombination and results in the excision of the 
loxP-flanked stop codon (LSL), thereby leading to conditional ex-
pression of KrasG12D and deletion of p53 specifically in the mouse 
pancreas (fig. S2A) (13, 14). The KPC;Acsl3−/− mice were born 
according to the expected Mendelian ratio and without obvious 
macroscopic defects during development or adult life compared to 
the KPC;Acsl3+/+ mice. We assessed tumor formation at 8 weeks 
after tamoxifen-mediated induction, a time point where the pancreas 
is occupied by low- and high-grade pancreatic cancer. The analysis 
of pancreata from KPC;Acsl3−/− mice evidenced a complete loss of 
Acsl3 mRNA, protein, and a reduction in total ACSL activity com-
pared to the KPC;Acsl3+/+ healthy and tumor tissue, confirming the 
knockout of Acsl3 (Fig. 2, A and B, and fig. S2B). In agreement with 
the human data (Fig. 1), tumor tissue of the KPC;Acsl3+/+ mice 
showed a marked increase in Acsl3 mRNA and total ACSL activity 
compared to healthy tissue (Fig. 2A and fig. S2B). Furthermore, re-
sults from our IHC analysis showed that, in the pancreata of these 
mice, ACSL3 is present in tumors, but not in the healthy surround-
ing tissue (Fig. 2B). We also found that within the tumor lesions, 
ACSL3 is broadly expressed in tumor cells and only to a limited 
extent in stromal fibroblasts as evidenced by costaining with 
basic cytokeratin, a marker of epithelial cells (colocalization score, 
68.23 ± 7.14%) and fibroblast activation protein  (FAP; colocal-
ization score, 3.63 ± 2.18%), respectively (Fig. 2C).
Histological evaluation of hematoxylin and eosin (H&E)–stained 
tissue sections revealed decreased disease progression in KPC;Acsl3−/− 
compared to KPC;Acsl3+/+ mice (Fig. 2D). Moreover, the pancreas 
weight of KPC;Acsl3−/− mice was slightly reduced compared to 
KPC;Acsl3+/+ (fig. S2C). The fibrotic tissue measured by both 
Masson trichrome and Sirius red staining was decreased in KPC;Acsl3−/− 
compared to KPC;Acsl3+/+ tumors (Fig. 2, E and F). This degree of 
reduction in desmoplastic tissue was further confirmed by a reduc-
tion in the myofibroblast markers –smooth muscle actin (SMA) 
and FAP (fig. S2D).
To better understand the mechanism leading to decreased tumor 
formation upon Acsl3 deletion, we evaluated tumor cell proliferation 
by Ki67 staining. We found that Acsl3 deletion reduced the percentage 
of Ki67+ cells in both tumor cells (Ki67+/cytokeratin+) and tumor 
stromal fibroblasts (Ki67+/SMA+) (Fig. 2, G and H). Notably, we 
did not detect an increase in cell death as evaluated by TUNEL (terminal 
deoxynucleotidyl transferase–mediated deoxyuridine triphosphate 
nick end labeling) assay (fig. S2E). Together, these data suggest that 
ACSL3 supports the progression to PDAC by enhancing both tumor 
and stromal cell proliferation.
The postnatal KPC model used for this study is highly relevant, 
as human PDAC is an adult-onset malignancy. However, in this 
model, Pdx1-Cre–mediated recombination is observed only in the 
islet and acinar cells (15), raising the possibility of a context-specific 
phenotype. To address this issue, we tested the impact of Acsl3 
knockout in a prenatal mouse model of PDAC in which Cre is ex-
pressed in almost all pancreatic cell types. We generated mice carry-
ing the LSL-KrasG12D/+ allele, homozygous for the p53floxflox allele, 
either Acsl3+/+ or Acsl3−/−, and bearing a transgene allowing a 
constitutive expression of the Cre recombinase under the pancreas- 
specific Pdx1 (Pdx1-Cre6tuv) promoter to generate two experimen-
tal groups: LSL-KrasG12D/+;p53flox/flox;Pdx1-Cre6tuv;Acsl3+/+ and 
LSL-KrasG12D/+;p53flox/flox;Pdx1-Cre6tuv;Acsl3−/− (hereafter KPCC;Acsl3+/+ 
and KPCC;Acsl3−/−, respectively) (fig. S2F). The Pdx1-Cre6tuv allele 
allows the expression of Cre recombinase under the pancreas-specific 
Pdx1 promoter starting at approximately embryonic day 8.5. At this 
time, the Pdx1 gene is expressed in pre-pancreatic endoderm, thus 
allowing Cre expression (hence tumor initiation) in virtually all 
pancreatic cell types (16–18). We sacrificed the mice at 6 weeks of 
age, a time point where the mouse pancreas is highly occupied by 
high-grade PDAC lesions. In agreement with our results from the 
inducible KPC model, pancreas weight, tumor area, and fibrotic 
tissue were markedly decreased in KPCC;Acsl3−/− compared to 
KPCC;Acsl3+/+ mice (fig. S2, G to I).
Acsl3 deletion blocks PDAC immunosuppression in mice
Preinvasive and invasive PDAC lesions from mouse models and 
human patients are characterized by a strong presence of immuno-
suppressive cell types including tumor-associated M2-like macro-
phages, myeloid-derived suppressor cells, and regulatory T cells 
(Tregs) with a concomitant lack of effector T cells (18–22). Notably, 
a growing amount of evidence indicates that tumor-associated fibrosis 
promotes PDAC progression partly by negatively regulating anti-
tumor immunity (23). Therefore, we investigated whether the re-
duced PDAC progression and fibrosis, upon Acsl3 knockout, was 
associated with changes in tumor immune cell infiltration.
First, we revealed a strong reduction of TAM infiltration in 
tumors of KPC;Acsl3−/− mice compared to KPC;Acsl3+/+ mice as 
shown by staining with the macrophage markers F4/80 and CD206 
(Fig. 3, A and B). Strikingly, we found that the number of alterna-
tively activated macrophages (M2) expressing Arg1 was reduced in 
KPC;Acsl3−/− pancreata compared to KPC;Acsl3+/+ (Fig. 3, C and D). 
The number of macrophages negative for Arg1 (F4/80+/Arg1−) was 
unaltered, suggesting that the macrophage decrease in KPC;Acsl3−/− 
pancreata was due to a decrease in the M2 macrophage population 
(Fig. 3E). Neutrophils have been recently identified as potential 
contributors to mutant Kras-induced lung cancer progression (24, 25). 
Thus, we assessed neutrophil abundance by Ly6g staining in 
pancreatic cancer tissue sections from KPC;Acsl3+/+ and KPC; 
Acsl3−/− mice, but we did not find any difference in neutrophil 
numbers (fig. S3A).
Next, we assessed the presence of Tregs by costaining with the 
surface marker CD4 and the nuclear transcription factor FoxP3 and 
found that the KPC;Acsl3−/− tumors contained 50% less Tregs compared 
to KPC;Acsl3+/+ tumors (Fig. 3F). Moreover, immunofluorescence 
analysis of CD3+/CD8+ cytotoxic T lymphocytes (CTLs) revealed a 
twofold increase in the number of CD8+ T cells in KPC;Acsl3−/− mice 
with a concomitant increase in granzyme B expression, indicative of 
functional CTLs (Fig. 3, G and H). Notably, the effect of Acsl3 loss 
on the different immune cell populations was tumor specific; as in 
the healthy Pdx1-CreERT2;p53flfl;Acsl3+/+ and Pdx1-CreERT2; p53flfl; 
Acsl3−/− mice, we did not detect differences in the total number of 
T cells (CD45+/CD3+), CD4+ T cells (CD45+/CD3+/CD4+), or CD8+ 
T cells (CD45+/CD3+/CD8+) (fig. S3B).
The decreased tumor immunosuppression upon Acsl3 deletion 
was also recapitulated in KPCC;Acsl3−/− compared to KPCC;Acsl3+/+ 
mice. Also in this context, we found that Acsl3 deletion leads to a 
strong decrease in the intratumoral number of M2-polarized 
macrophages (F4/80+/Arg1+) and Tregs (CD4+/FoxP3+) and a signif-
icant increase in the number of CTLs (CD3+/CD8+) (fig. S3, C to E). 
Together, our results in PDAC mouse models strongly suggest that 
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the loss of ACSL3 lowers immunosuppression and improves the 
antitumor CTL response.
ACSL3 promotes the expression of PAI-1 in PDAC
Our results show that Acsl3 is mainly expressed in tumor cells 
(Fig. 2C), suggesting that the reduction of tumor fibrosis and immuno-
suppression in Acsl3 knockout mice is specifically due to Acsl3 dele-
tion in tumor cells. Thus, we hypothesized that Acsl3 deletion could 
interfere with the cross-talk between tumor and stromal cells by 
affecting the secretion of soluble factors from tumors such as cyto-
kines. To test this hypothesis, we used a healthy human pancreatic 
ductal epithelial cell line (HPDE), which harbors a doxycycline 
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Fig. 2. Acsl3 knockout reduces tumor fibrosis and suppresses tumor progression. (A) Acsl3 mRNA levels from healthy tissue (Kras+/+;p53flox/flox) either Acsl3+/+ or 
Acsl3−/− and dissected tumors from LSL-KrasG12D/+;p53flox/flox;Pdx1-CreERT2;Acsl3+/+ (KPC;Acsl3+/+) and KrasG12D/+;p53flox/flox;Pdx1-CreERT2;Acsl3−/− (KPC;Acsl3−/−) (n = 3 mice per 
group). (B) Representative IHC staining images of ACSL3 from KPC;Acsl3+/+ and KPC;Acsl3−/− pancreas sections representing healthy and tumor tissue. Scale bars, 50 m. 
(C) Representative images of immunofluorescent staining for basic cytokeratin (top, green), ACSL3 (red), nuclei (blue), and FAP (bottom, green) of KPC;Acsl3+/+ tumor-bearing 
pancreas sections. Scale bars, 70 m. (D) Representative images of H&E-stained (top, left) and basic cytokeratin–stained (bottom, left) tumor-bearing pancreas sections 
and pancreas tumor area quantification (right) reported as percentage of tumor area per total pancreas area from H&E-stained mouse pancreas sections of KPC;Acsl3+/+ 
(n = 15) and KPC;Acsl3−/− (n = 8) mice. Scale bars, 70 m (top) and 50 m (bottom). (E) Representative images of Sirius red–stained (top) and Masson trichrome–stained 
(bottom) mouse pancreatic cancer sections of KPC;Acsl3+/+ and KPC;Acsl3−/− mice. Scale bars, 70 m (left) and 30 m (right). (F) Quantification of fibrosis based on Sirius 
red and Masson trichrome staining, respectively, reported as % of area occupancy over tumor area assessed on a representative pancreas section per mouse (n = 5 to 
6 mice per group). (G) Representative immunofluorescence staining for basic cytokeratin, Ki67, and nuclei (Hoechst) (left) and relative quantification (right) of KPC;Acsl3+/+ 
and KPC;Acsl3−/− tumor-bearing pancreas sections. The quantifications are the average of 15 pictures per mouse (n = 5 mice per group). Scale bars, 50 m. (H) Represen-
tative immunofluorescence staining for SMA, Ki67, and nuclei (Hoechst) (left) and relative quantification (right) of KPC;Acsl3+/+ and KPC;Acsl3−/− pancreatic cancer tissue 
sections. The quantifications are the average of 15 pictures per mouse; n = 5 mice per group. Scale bars, 50 m. Error bars represent mean ± SD; statistical analysis was 
performed using Student’s t test or one-way ANOVA. *P < 0.05 and **P < 0.01.
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(Dox)–inducible oncogenic KRASG12D expression (thereafter named 
HPDEK) (26). In these cells, Dox treatment for 24 hours induced 
KRASG12D expression and increased the ACSL3 transcription, protein 
level, and the total ACSL activity (Fig. 4A and fig. S4, A and B). 
Notably, the increased ACSL activity was completely abolished by 
ACSL3 knockdown (Fig. 4A). Next, we transduced the HPDEK cells 
with either an empty vector control or a short hairpin RNA (shRNA) 
against ACSL3 and measured the relative levels of 36 cytokines in 
the culture supernatant using a human cytokine array. The only sig-
nificant difference identified by this analysis was a reduction in 
plasminogen activator inhibitor type 1 (PAI-1) upon ACSL3 knock-
down (fig. S4, C and D). The PAI-1 decrease was confirmed by 
quantitative real-time polymerase chain reaction (qPCR) and 
immunoblot with a second shRNA against ACSL3 (Fig. 4, B and C). 
Moreover, qPCR from mouse tumor samples evidenced a decrease 
in Pai-1 mRNA in KPC;Acsl3−/− tumors compared to KPC;Acsl3+/+ 
tumors, additionally confirming our in vitro results (Fig. 4D). 
Last, KRASG12D induction with Dox increased the transcriptional and 
protein level of PAI-1 in HPDE cells (fig. S4, E and F).
PAI-1 is a profibrotic TGF-–responsive gene and has been 
shown to be positively regulated by long-chain unsaturated fatty 
acids including oleic and linoleic acid (27). To assess causality 
between ACSL3 and PAI-1 levels, we supplied cells with oleic acid, 
which is also a lipid substrate of ACSL3, to lipid-starved HPDEK 
cells with or without ACSL3 knockdown. qPCR and immunoblot 
analysis evidenced that oleic acid increased the transcriptional and 
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protein levels of PAI-1, and this was abolished by ACSL3 knock-
down, additionally confirming that ACSL3 is necessary for PAI-1 
induction (Fig. 4, E and F).
In KPC;Acsl3+/+ pancreatic tissue, PAI-1 was mainly localized in 
cancer cells (Fig. 4G; colocalization score PAI-1/basic cytokeratin: 
78.27 ± 4.11%) and appeared enriched at their periphery and in 
close contact with the adjacent stromal cells (Fig. 4G, insets). More-
over, PAI-1 only minimally colocalized with both fibroblast markers 
FAP and SMA in KPC;Acsl3+/+ tumors (colocalization PAI-1/FAP: 
7.61 ± 0.87% and PAI-1/SMA: 5.23 ± 1.62%; fig. S4G). Markedly, 
PAI-1 was significantly decreased in Acsl3−/− tumors compared to 
Acsl3+/+ tumors (Fig. 4H).
To evaluate whether PAI-1 and ACSL3 expression levels are 
positively correlated in human patient-derived PDAC, we performed 
an analysis on publicly available RNA-sequencing data from The 
Cancer Genome Atlas (TCGA; subset PAAD) (28). For this analysis, 
we took into consideration only KRAS-mutated samples (thereafter 
named PAAD-K). PDAC samples evidenced a significantly higher 
PAI-1 expression levels compared to healthy pancreatic tissue (Fig. 4I). 
Furthermore, immunoblot analysis of PAI-1 in matched healthy 
and tumor patient-derived tissue revealed a marked increase in 
PAI-1 protein level in tumor tissue (Fig. 4J). Further analysis evi-
denced a positive correlation between the expression levels of PAI-1 
and ACSL3, suggesting a co-regulation in PDAC (Fig. 4K).
Tumor-derived PAI-1 supports PDAC progression
PAI-1 belongs to the superfamily of serine-protease inhibitors, 
which, by inhibiting the urokinase-type plasminogen activator and 
plasmin-dependent matrix metalloproteinases, promotes fibrosis 
(29, 30). Furthermore, recent evidence suggested that PAI-1 promotes 
M2 macrophage polarization, thus stimulating immunosuppression 
(31). Our findings indicated that PAI-1 is produced and secreted by 
pancreatic cancer cells in vitro (fig. S4D), and it is enriched in the 
outer edge of cancer cells, next to stromal components (Fig. 4G and 
fig. S4G). Moreover, the KPC;Acsl3−/− tumors displayed reduced fibrosis 
and immunosuppression (Figs. 2 and 3). Thus, our data suggest that 
PAI-1 may be a key intermediate of tumor/stroma cross-talk, mediat-
ing immunosuppression and fibrosis in PDAC. To assess the impact 
of tumor-derived PAI-1 on tumor/stroma interaction, we used a 
cancer cell line derived from a mouse pancreatic cancer model, 
KrasG12D;p53R172H (thereafter named KP cells) (8). Orthotopic in-
jection of these cells in the pancreata of immunocompetent mice 
generates a spontaneous stromal response and displays common 
patterns with disease progression (32). To confirm that the KP cells 
are relevant concerning PAI-1 regulation, we transduced cells with 
an shRNA against Acsl3 or an empty vector control and performed 
a mouse cytokine array comprising 111 cytokines. We found that 
PAI-1 was one of the most significantly decreased cytokines follow-
ing Acsl3 knockdown in KP cells (fig. S4H). Moreover, this analysis 
revealed a decrease in the level of additional proteins associated 
with collagen deposition and remodeling including collagen type 
XVIII alpha 1 (Col18a1), insulin-like growth factor binding protein 
3 (IGFBP3), and matrix metalloproteinase 3 (MMP3), corroborat-
ing the ACSL3-mediated decrease in collagen deposition (fig. S4H).
Knockdown of Pai-1 in KP cells did not affect cancer cell prolif-
eration compared to the shRNA control in vitro (fig. S4, I and J). 
However, when we orthotopically injected the pancreata of immuno-
competent mice with the KP cells transduced with either a vector 
control or an shRNA against Pai-1, we found that the suppression of 
Pai-1 reduced tumor growth, as shown by the reduced pancreata 
weight and reduced both cancer cell and stromal fibroblast prolif-
eration (Fig. 4L and fig. S4K). Notably, confirming the profibrotic 
role of PAI-1, we found a marked reduction in tumor fibrosis as 
evidenced by Masson trichrome staining (Fig. 4M). Moreover, Pai-1 
knockdown decreased the number of tumor alternatively activated 
macrophages (F4/80+/Arg1+) and Tregs (CD4+/FoxP3+) with a con-
comitant increase in CTL cells expressing granzyme B, suggesting a 
stronger antitumor cytotoxicity (Fig. 4, N and O, and fig. S4, L and M). 
Together, these data indicate that tumor-derived PAI-1 mediates 
fibrosis, immunosuppression, and progression of PDAC.
PAI-1 expression level correlates with the levels of fibrosis 
and immunosuppression markers and predicts poor PDAC 
patient survival
To confirm the relevance of PAI-1 signaling in human PDAC, we 
assessed the correlation between the expression level of PAI-1 and 
markers of fibrosis and immunosuppression in human pancreatic 
tumor patients’ samples (cohort PAAD-K). Our analysis revealed a 
positive correlation between the expression level of PAI-1 and 
COL11A1, a gene mediating extracellular matrix remodeling (Fig. 5A). 
Next, we found a positive correlation between the expression level 
of PAI-1 and markers of Tregs, CD4, and FoxP3 (Fig. 5B). Moreover, 
our analysis evidenced a positive correlation between the expression 
levels of CD4 and FoxP3 (Fig. 5C). Thus, our results suggest an 
increase of immunosuppressive Treg population in high PAI-1– 
expressing tumors. Further supporting the immunosuppressive 
role of PAI-1 in PDAC, our data evidenced a positive correlation 
between the expression levels of PAI-1 and those of CD11b (pan- 
macrophage marker) or CD206 (M2 macrophage marker), as well 
as between the expression levels of these two macrophage markers 
(Fig. 5, D and E). These results indicate a higher tumoral infiltration 
of M2 macrophages in tumors with higher PAI-1 expression levels. 
Adding further value to our findings, our analysis evidenced that 
the survival rate of patients with high PAI-1–expressing tumors was 
significantly lower compared to that of patients with low PAI-1– 
expressing tumors (Fig. 5F).
PAI-1 inhibition enhances the responsiveness of PDAC 
tumors to chemo- and immunotherapy
Our results suggest that the ACSL3–PAI-1 pathway is a crucial node 
in PDAC progression by promoting fibrosis and immunosuppression. 
To give therapeutic value to our findings, we sought to combine 
PAI-1 inhibition with chemotherapy and checkpoint immunotherapy. 
To this aim, we established syngeneic orthotopic tumors derived from 
KP cancer cells, and we tested whether the treatment with tiplaxtinin, 
an orally available and selective PAI-1 inhibitor (33), could improve 
the efficacy of a combination therapy using standard chemotherapy 
(gemcitabine) and immunotherapy with PD-1 (programmed cell 
death protein 1) antagonists (anti-PD1) (Fig. 6A). Notably, in vitro 
treatment of cancer cells with tiplaxtinin did not affect cell prolifer-
ation (fig. S5A). We found that treatment of mice with tiplaxtinin or 
gemcitabine/anti-PD1 for 2 weeks led to a modest antitumor response 
as evidenced by the pancreas weight and overall mice survival com-
pared to the placebo-treated mice (Fig. 6, B and C). However, the 
treatment with gemcitabine/anti-PD1 in combination with tiplaxtinin 
suppressed tumor weight and improved the overall survival of mice 
(Fig. 6, B and C). Notably, the number of lung metastases was signifi-
cantly suppressed only in tiplaxtinin/gemcitabine/anti-PD1–treated 
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compared to the placebo-treated mice (fig. S5, B and C). The re-
duced metastasis coincided with a reduction in vessel density in the 
tiplaxtinin/gemcitabine/anti-PD1–treated mice (fig. S5D). Staining 
of mouse tumor tissue with Masson trichrome evidenced reduced 
fibrosis in the tiplaxtinin/gemcitabine/anti-PD1–treated mice com-
pared to placebo-, tiplaxtinin-, and gemcitabine/anti-PD1–treated 
mice (Fig. 6, D and E). Moreover, both tumor and stromal cells from 
tiplaxtinin/gemcitabine/anti-PD1–treated mice showed reduced pro-
liferation and increased apoptosis as evidenced by Ki67 and TUNEL 
assay, respectively (Fig. 6, F to H, and fig. S5E).
Next, we found that the tiplaxtinin/gemcitabine/anti-PD1 treat-
ment led to a reduction in the number of tumor M2 macrophage 
infiltration as shown by the reduced number of macrophages co-
expressing F4/80 and Arg1 (F4/80+/Arg1+) compared to the placebo 
treatment (Fig. 6, I and J, and fig. S5F). Notably, the gemcitabine/
anti-PD1–treated mice showed no change in the number of tumor- 
infiltrated macrophages, suggesting a PAI-1–specific effect (Fig. 6J). 
Moreover, the tumors of the tiplaxtinin-, gemcitabine/anti-PD1–, and 
tiplaxtinin/gemcitabine/anti-PD1–treated mice displayed reduced 
infiltration of Tregs compared to the placebo (Fig. 6, I and K) with a 
concomitant increase in granzyme B+ cytotoxic CD8+ immune cell 
population (Fig. 6, I, L, and M). Collectively, these data suggest that 
combination of gemcitabine with PD1 and PAI-1 inhibition may be 
an effective therapeutic approach to reduce fibrosis and immuno-
suppression and increase tumor-specific immunity in PDAC.
DISCUSSION
The highly desmoplastic stroma and extensive tumor infiltration by 
immunosuppressive cell populations are considered key attributes 
of PDAC progression and resistance to therapy (34–36). Thus, deci-
phering the mechanisms by which PDAC engages its stromal fibrotic 
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and immunosuppressive components is of great scientific interest 
and potential translational importance. In this study, we identified 
the ACSL3–PAI-1 signaling axis as a critical regulator of desmoplasia 
and immunosuppression in PDAC. We showed that ACSL3 con-
tributes to PDAC progression by driving the production and secretion 
of the profibrotic protein PAI-1 from tumor cells. Either Acsl3 knock-
out or suppression of tumor-derived Pai-1 hinders the expansion of 
cancer-associated fibroblasts and extracellular matrix deposition and 
hampers the infiltration of immunosuppressive cell populations in 
tumors, including M2-like macrophages and Tregs.
Previous evidence suggests that knockdown of ACSL3 in primary 
hepatocytes decreases the activity of several lipogenic transcription 
factors including sterol regulatory element-binding protein-1c 
(SREBP1c), a positive regulator of TGF- signaling (37, 38). PAI-1 
is a TGF-–responsive gene, suggesting that ACSL3 may regulate 
PAI-1 through TGF-. Future studies are warranted to understand 
the role of ACSL3 in TGF- signaling pathway in pancreatic cancer.
The effects of stromal ablation in PDAC remain controversial. 
Recent studies provided evidence that stromal elements can act by 
restraining PDAC rather than supporting its progression. For instance, 
Hedgehog deletion specifically in tumors of a mouse model of 
pancreatic cancer (Pdx1-Cre;KrasLSL-G12D/+;p53fl/+) decreased stromal 
content but resulted in more aggressive, poorly differentiated, and 
highly vascularized tumors (39). Moreover, depletion of SMA+ 
fibroblasts during pancreatic cancer development accelerated disease 
progression and decreased mouse survival (40). Furthermore, other 
studies highlighted the therapeutic potential of targeting other 
components of desmoplastic stroma such as PSCs (11, 41). In this 
context, during activation, PSCs undergo extensive lipid metabolic 
remodeling and secrete lysolipids to support PDAC progression 
(11). Given the avidity of mutant KRAS for extracellularly derived 
fatty acids (10, 42, 43), it would be of interest to assess whether 
ACSL3 is indispensable for the activation of lipids released by acti-
vated PSCs in PDAC. Related to this, PAI-1 has been shown to con-
tribute to the activation of PSCs (44), hinting toward a feedback 
loop that sustains PSC activation. Accordingly, our work reveals 
that it is specifically the tumor-derived PAI-1 that promotes the 
tumor immunosuppressive microenvironment and fibrosis leading 
to increased PDAC progression.
In solid tumors such as non–small cell lung cancer and kidney 
cancer, immunotherapy using immune checkpoint–blocking anti-
bodies has shown remarkable clinical efficacy (45, 46). In contrast, 
immunotherapy has been proven to be ineffective for pancreatic 
cancer treatment and gemcitabine remains the main treatment 
option (47, 48). The reasons for the lack of efficacy are still unclear 
but could be caused by the excessive desmoplasia and poor immuno-
genicity (49, 50). Here, we assessed the efficacy of a combination 
therapy using standard chemotherapy (gemcitabine) and immuno-
therapy (anti-PD1) with tiplaxtinin, an orally available inhibitor of 
PAI-1 in a mouse model of PDAC. Our data show that the treat-
ment with tiplaxtinin caused a marked reduction of tumor fibrosis 
and immunosuppression, while it enhanced cytotoxic T cell response. 
This effect was associated with increased efficacy of chemotherapy/
immunotherapy as shown by stronger suppression of tumor growth 
and metastases formation as well as increased overall mice survival. Thus, 
our data reveal PAI-1 as a druggable target for PDAC treatment.
We found increased levels of activated CD8+ tumor-infiltrating 
T cells despite the fact that we detected reduced CD31+ blood vessel 
density. However, we revealed a strong reduction of immuno-
suppressive cell populations that can explain the increased CD8+ 
T cell tumor infiltration. In contrast, a recent study revealed that 
combination of mitogen-activated protein kinase kinase (MEK) and 
cyclin-dependent kinase 4/6 (CDK4/6) inhibitors triggers senescence- 
associated secretory phenotype (SASP)–mediated increase in CD31+ 
cells and endothelial activation, promoting CD8+ T cell tumor infil-
tration. Notably, the infiltration of CD8+ T cells in PDAC occurred 
without any changes in immunosuppressive cell populations but 
was dependent on vascular cell adhesion molecule 1 (VCAM1)– 
dependent endothelial activation (51). These results suggest that 
qualitative changes in endothelial cell activation may have a greater 
impact on the immune landscape of PDAC than changes in blood 
vessel density.
PAI-1 inhibitors have so far provided antithrombotic benefits 
without causing bleeding in many preclinical models including 
nonhuman primates (52, 53). Unfortunately, treatment with tiplaxtinin 
has been unsuccessful in human clinical trials for thrombosis due to 
an unfavorable risk to benefit ratio and the need for tight dose 
control to avoid provoking bleeding disorders. However, the use of 
tiplaxtinin, or other PAI-1 inhibitors, for cancer treatment still has 
to be evaluated. Our preclinical data suggest that the addition of 
PAI-1 inhibitors in chemotherapy and checkpoint immunotherapy 
holds promise for the treatment of pancreatic cancer. Fibrosis and 
immunosuppression are common features of many types of malig-
nancies. Furthermore, data suggest that high levels of PAI-1 are 
associated with poor clinical outcomes and chemo- or targeted therapy 
resistance in different types of cancer (54–57). Therefore, further 
trials are warranted to validate similar combination strategies with 
PAI-1 inhibitors for the treatment of other cancer types.
MATERIALS AND METHODS
Experimental models
Cell lines
HPDE-iKRASG12D cell line was a gift of K. L. Scott (26). The HPDE- 
iKRASG12D cell line was DNA fingerprinted for provenance and screened 
for mycoplasma and cultured in an incubator at 37°C and 5% CO2 for 
one passage in KSFM (keratinocyte serum-free media) (Gibco) and 
supplied with epidermal growth factor and bovine pituitary extract as 
prescribed by Gibco. Subsequently, cells were transferred in RPMI 1640 
(Gibco) supplied with 10% fetal bovine serum (FBS) and penicillin/
streptomycin for at least two passages. Expression of KRASG12D was 
induced by administration of Dox (Fisher Scientific, BP2653) in the 
culture medium to a concentration of 500 ng/ml for 24 hours.
The KPC/WCB3 cell line (C57BL/6J background) used for the 
KP orthotopic PDAC mouse model was obtained from Ximbio on 
behalf of Cancer Research Technology Ltd. and cultured in Dulbecco’s 
Modified Eagle medium (DMEM) (Gibco) supplied with 10% FBS 
and penicillin/streptomycin in an incubator at 37°C and 5% CO2.
Human studies
The patient-derived frozen PDAC samples were provided by the 
Institute of Pathology, Translational Research Unit. All the patients 
were females. The TMA was provided by E. Karamitopoulou, Institute 
of Pathology, University of Bern. The use of human samples was 
approved by the ethics commission (Swissethics), ID: 2017-01322. 
All samples were provided upon patient consent.
Mice
The mixed background tamoxifen-inducible LSL-KrasG12D/+;Trp53fl/fl; 
Pdx1CreERT2;Acsl3−/− mouse model was obtained by crossing the 
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strain Tg(Pdx1-cre/Esr1*)#Dam/J (15) (from The Jackson Laboratory, 
stock number 024968) with B6.129SS4-krastm4Tyj/J (13) (from The 
Jackson Laboratory, stock number 008179), B6.129P2-Trp53tm1Brn/J 
(14) (from The Jackson Laboratory, stock number 008462), and 
B6;129S5-Acsl3Gt(OST148301)Lex/Orl (constitutive Acsl3−/− mouse, 
obtained from the European Mouse Mutant Archive). The B6;129S5- 
Acsl3Gt(OST148301)Lex/Orl mice carry a gene trap disrupting Acsl3 
upstream of exon 1. Mice were backcrossed for 12 generations, 
before creating the experimental groups. The constitutive prenatal 
pancreas Cre-expressing LSL-KrasG12D/+;Trp53flfl;Pdx1-Cre6Tuv;Acsl3−/− 
mouse model was obtained by crossing strain B6.FVB-Tg(Pdx1- 
cre)6Tuv/J (18) (from The Jackson Laboratory, stock number 014647) 
with B6.129SS4-krastm4Tyj/J (from The Jackson Laboratory, stock 
number 008179), B6.129P2-Trp53tm1Brn/J (from The Jackson Labo-
ratory, stock number 008462), and B6;129S5-Acsl3Gt(OST148301)
Lex/Orl. Mice were backcrossed for eight generations before creat-
ing the experimental groups. For the KP orthotopic PDAC mouse 
model, we used the strain C57BL/6J (Charles River Laboratories). 
Only male littermates were used for the experiments. Animal 
handling and experimental procedures were performed in compli-
ance with the federal guidelines and were approved by the Veterin-
aerdienst des Kantons Bern. The full list of all mouse strains and cell 
lines used can be found in table S1.
Reagents and plasmids
Induction of the expression of KRASG12D was performed by supple-
menting cell culture medium with Dox (500 ng/ml; Fisher Scientific, 
BP2653). For lentiviral production, the pCMV-VSV-G (Addgene, 
plasmid #8454) and pCMV-dR8.2 dvpr (Addgene, plasmid #8455) 
and pLKO.1 hygro (Addgene plasmid #24150) plasmids were a gift 
from B. Weinberg (58). The human ACSL3-containing plasmid 
(pEGFP-C1 ACSL3HA) used to reexpress ACSL3 upon knockdown 
was provided by J. Füllekrug (59).
shRNAs, virus production, and transduction
The validated shRNAs were obtained as bacterial glycerol stock from 
Sigma-Aldrich. Recombinant lentiviruses were produced by transfect-
ing human embryonic kidney (HEK) 293T cells, using the TransIT-293 
Transfection Reagent (Mirus, MIR2705), with pCMV-VSV-G 
(VSV-G protein), pCMV-dR8.2 (lentivirus packaging vector), and 
lentiviral constructs, according to the manufacturer’s instructions. 
The full list of the shRNA sequences used in this manuscript can be 
found in table S1.
Animal studies
Mice were maintained under controlled humidity and temperature 
conditions, with a standard 12-hour light/12-hour dark cycle, and 
were fed ad libitum. Genomic DNA extraction and PCR assay were 
performed using the KAPA HotStart Mouse Genotyping Kit (Kapa 
Biosystems, KK7352) and KAPA2G Fast HotStart Genotyping Mix 
(Kapa Biosystems, KK5621), respectively, according to the manu-
facturer’s instructions. The mice genotypes were confirmed follow-
ing the corresponding The Jackson Laboratory protocols. The PCR 
for the Acsl3 genotyping was performed according to the KAPA 
HotStart Mouse Genotyping Kit with an annealing temperature at 
60°C. The full list of oligos used to genotype the mice can be found 
in table S1. Recombination in KPC mice was induced with five 
consecutive daily administrations of tamoxifen with intraperitoneal 
injection at 3 weeks of age. The injected solution contained tamox-
ifen presolubilized in ethanol and diluted in sunflower oil (Sigma- 
Aldrich) with a proportion of 1:9 parts ethanol/sunflower oil. 
Tamoxifen (2.5 mg) was administered per mouse with each injection. 
The KPC mice were sacrificed 8 weeks after induction (11 weeks of 
age), while the KPCC mice were sacrificed at 6 weeks of age. Pancreata 
were retrieved after anesthesia and perfusion of the animal with 
20 ml of phosphate-buffered saline (PBS).
For the orthotopic KP model, we injected 200,000 cells per mouse 
directly in the pancreas as previously described (60). Tiplaxtinin 
(Tocris Bioscience) was presolubilized in dimethyl sulfoxide (DMSO) 
(stock concentration, 40 mg/ml) administered at a dose of 20 mg/kg 
with oral gavage every second day. After presolubilization in DMSO 
(Sigma-Aldrich), the vehicle used for dilution was corn oil (Sigma- 
Aldrich) to a total volume of 100 l per mouse. Gemcitabine was 
administered at a dose of 60 mg/kg with intraperitoneal injection 
every fourth day diluted from a stock (50 mg/ml) in PBS (total volume 
injected, 100 l per mouse). The anti-PD1 monoclonal antibody 
(mAb) and isotype control (Bio X Cell) were diluted in PBS and 
administered at a dose of 200 g per mouse via intraperitoneal 
injection every fourth day (100 l per mouse). Tiplaxtinin was ad-
ministered every other day, while gemcitabine and PD1 mAb were 
administered every 4 days. The treatment scheme included a total of 
eight administrations of tiplaxtinin and four administrations of 
gemcitabine and anti-PD1 mAb. Mice were sacrificed 21 days after 
KP cell implantation. In the Pai-1 knockdown KP orthotopic mod-
el, the mice were sacrificed 15 days after KP cell implantation.
The lung metastases were quantified from the average of three 
tissue sections of paraffin-embedded and H&E-stained whole lung 
tissue separated by approximately 30 m from each other. The number 
of metastases was expressed as the number of metastases per lung.
Reverse transcription PCR
RNA was extracted using the RNeasy Kit (Qiagen, 74104), and 
complementary DNA (cDNA) was synthesized with the RevertAid 
First-Strand cDNA Synthesis Kit (Thermo Fisher Scientific, K1622). 
qPCR was performed in 96-well plates (TreffLab) with Fast SYBR 
Green (Thermo Fisher Scientific, 4367659). The normalization was 
performed with the CT method. The full list of the oligonucleotides 
used can be found in table S1.
Histology
Tissues for histology were fixed at 4°C overnight in 4% paraformal-
dehyde in PBS before paraffin embedding. All sections used for his-
tological analysis were 5 m thick. Histological characterization and 
consequent scoring of neoplastic lesion grade of H&E-stained 
sections of pancreata were done with supervision and confirmation 
from a pathologist. Tumor burden was assessed by digital quantifi-
cation of the area occupied by tumors compared to unaffected tissue 
using QuPath v.0.1.2.
Immunohistochemistry
IHC was conducted on paraffin-embedded tissue. Sections were 
deparaffinized, rehydrated through a graded series of ethanol solu-
tions, and subjected to antigen retrieval by boiling for 12 min in 
antigen retrieval sodium citrate buffer (pH 6). Sections were then 
pretreated for 30 min with 3% hydrogen peroxide (Sigma-Aldrich, 
216763) in PBS, washed twice with 0.1 M tris-buffered saline (TBS), 
blocked for 1 hour in 2% bovine serum albumin (BSA) in TBS con-
taining 0.1% polysorbate 20 (TBS-T) and 10 min in 2.5% normal 
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horse serum (Vector Laboratories, #S-2012), and incubated with 
primary antibodies diluted appropriately in blocking solution. The 
following day, sections were washed in TBS-T and incubated with 
ready-to-use secondary antibody (Vector Laboratories, #MP-7401) 
for 1 hour or with Mouse on Mouse (M.O.M.) ImmPRESS Peroxidase 
Polymer Anti-Mouse Reagent (Vector Laboratories, #MPX-2402) for 
10 min, and the staining was revealed with DAB+ solution (Dako, 
#Κ3467). Tissue sections were then counterstained with methyl 
green (Vector Laboratories, #H-3402), dehydrated, and mounted. 
Stained sections were scanned using a Panoramic MIDI II digital 
slide scanner (3DHISTECH Ltd). Image analysis was performed 
using QuPath (open source software, v.0.1.2).
TMA staining and scoring
The TMA IHC staining with anti-ACSL3 (Thermo Fisher Scientific, 
catalog no. PA5-29507) was performed as previously described 
(10). The antigen retrieval method consisted of a 20-min, 95°C in-
cubation in a sodium citrate buffer solution at pH 6. The antibody 
dilution was 1:300, and the incubation time was 30 min at room 
temperature. The TMA scoring was done by a pathologist with 
experience on human pancreatic cancer (E.K.). We scored for low, 
intermediate, or high ACSL3 protein levels based on a histological 
score that takes into consideration the percentage of cells stained at 
different intensities (H-score). We considered an H-score of less than 
100, from 100 to 200, and above 201 having a low, intermediate, or high 
staining intensity, respectively. The scoring of fibrosis was done by 
quantification of Masson trichrome–positive tissue with the QuPath 
software. The blue RGB channel area was automatically analyzed 
and quantified with the quantification module and expressed as 
mean pixel intensity (occupancy weighted by staining intensity).
Immunofluorescence
For immunofluorescence conducted on paraffin-embedded tissue, 
all stainings with primary antibodies were done after deparaffinization, 
rehydration through a graded series of ethanol solutions, antigen 
retrieval by boiling for 10 min in sodium citrate buffer (pH 6), and 
blocking in 2% BSA in PBS-T buffer. Antibodies were diluted in 
blocking solution, and antibody incubation was done at 4°C over-
night. Secondary fluorescent-tagged antibodies were from molecular 
probes (Invitrogen). Stained cells and sections were scanned using a 
Panoramic MIDI II digital slide scanner (3DHISTECH Ltd.) or 
with a confocal microscope (Carl Zeiss). Image analysis was per-
formed with Imaris software (www.bitplane.com).
Immunoblotting
Cells were lysed in radioimmunoprecipitation assay (RIPA) buffer 
[50 mM tris-HCl (pH 8.0), 150 mM NaCl, 1.0% NP-40, 0.5% sodium 
deoxycholate, and 0.1% SDS] containing complete EDTA-free pro-
tease inhibitors (Roche) and 1 mM phenylmethylsulfonyl fluoride. 
Human samples were first pulverized in a liquid nitrogen mortar 
and homogenized in RIPA buffer before lysis incubation. Samples 
were resolved by SDS–polyacrylamide gel electrophoresis in Bio-Rad 
blotting chamber, transferred to nitrocellulose membrane using a 
semidry chamber (Bio-Rad), and blocked in 5% BSA. Membranes 
were then incubated overnight at 4°C with primary antibody diluted 
in 5% BSA in PBS containing 0.1% Tween. Secondary fluorescent- 
tagged antibodies were from LI-COR Biosciences, and development 
was done in LI-COR fluorescence-chemiluminescence detector. All 
antibodies and their dilutions are listed in table S1.
FACS analysis
For the flow cytometry experiment, 40 l of blood was taken with a 
capillary glass tube from the tail of each mouse. Blood was kept on 
ice and immediately centrifuged at 1400 rpm for 7 min. The super-
natant was removed, and the residual cells were resuspended in 100 l 
of fluorescence-activated cell sorting (FACS) buffer (PBS supplied 
with 2% FBS). Red blood cells were osmotically lysed with the RBC 
lysis buffer (BioLegend, #420301) according to the manufacturer’s 
instructions. Cells were then centrifuged at 1400 rpm for 7 min, and 
the supernatant was removed and washed three times with 1 ml 
of FACS buffer. Subsequently, they were resuspended in 100 l of 
blocking buffer for 30 min on ice. The blocking buffer consisted of 
one-third supernatant from HB-197 cells [Fc (fragment crystallizable) 
region blocker], one-third FACS buffer, and one-third of equally mixed 
rat, hamster, rabbit, mouse, and FBS. Antibodies were added directly 
to the sample and incubated for 1 hour on ice in the dark. Afterward, 
cells were centrifuged once at 1400 rpm for 7 min, the supernatant 
was removed, and the cell pellet was washed three times with 1 ml 
of FACS buffer. The cell pellet was resuspended in 100 l of FACS 
buffer and immediately measured with a BD FACSVerse. Cells were 
gated according to their forward and side scatter values to exclude cell 
clusters. CD45+ events were recorded and subgated as shown in fig. S3B.
ACSL enzymatic activity assay
The ACSL activity was measured in homogenate and cell fractions 
by a radioisotopic assay of labeled palmitate incorporation into 
palmitoyl CoA. The assay mixture contained 175 mM tris-HCl (pH 7.4), 
8 mM MgCl2, 5 mM dithiothreitol, 1 mM adenosine triphosphate 
(ATP), 0.2 mM CoASH, and 50 M palmitate containing 0.3 Ci of 
[3H]palmitic acid in a solution of 0.5 mM Triton X-100 with 10 M 
EDTA. The reaction was initiated by addition of 10 to 30 g of cell 
fraction protein. The total volume was 200 l in each assay. The re-
action was terminated after 10 min at room temperature by addi-
tion of 1 ml of Dole’s reagent (isopropanol:heptane:1 M H2SO4, 40:10:1 
by volume). Heptane (2 ml) and H2O (0.5 ml) were added, and the 
upper layer was removed. The lower layer was washed with 2 ml of 
heptane, and the top phase was removed. Scintillation mixture con-
tained scintillation fluid and lower phase in a 1:1 ratio, and it was 
read in the volume of 100 l on a white 96-well plate (PerkinElmer) 
with a scintillation plate reader (Packard Bioscience). ACSL activity 
is expressed as nanomoles per milligram of protein per minute.
Cytokine array
The Cayman Human cytokine array (catalog no. ARY005) and the 
Mouse cytokine array (catalog no. ARY028) were used to perform 
the assays. In both cases, 150,000 cells were plated in a six-well plate, 
and the day after, cell culture medium was refreshed. Supernatant 
from cultured cells was collected after 24 hours of incubation, and 
the assay was performed according to the manufacturer’s instructions. 
Acquisition of the array image was performed with the LI-COR 
instrument on the chemiluminescent channel, and optical density 
was quantified with the Image Studio software (www.licor.com).
Colocalization analysis
The analyses were performed using the Imaris Studio Software. 
To exclude false positivity because of the background of the green 
channel, a first mask was set on it, with a threshold value of “1” for 
bright intensity. The analysis was run with the Imaris CoLoc and 
Imaris Cell identification tools, and the results are the average of at 
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least 15 pictures per mouse section. The number of mice per group 
is indicated in the figure legends. For the colocalization between basic 
cytokeratin and Ki67, we run the algorithm “cell identification”; for 
the value “nucleus,” the blue channel [4′,6-diamidino-2-phenylindole 
(DAPI)] was selected; for the value “positive,” the red channel (Ki67) 
was selected; and for the “membrane” value, the green channel (basic 
cytokeratin) was selected.
For the colocalization between SMA and Ki67, we run the algo-
rithm cell identification, and we selected the blue channel (DAPI) 
for the nuclei; for the value positive, the red channel (Ki67) was 
selected; and for the membrane value, the green channel (SMA) was 
selected. The results of at least 15 pictures were averaged for every 
mouse and plotted. Tumor microvessel density was quantified on 
CD31-stained sections by following the Weidner method, and CD31 
occupancy was quantified with the open source software QuPath.
Database analysis
Data from the TCGA dataset PAAD were downloaded from the web 
GUI Xena Browser. They are expressed as RSEM (RNAseq by 
expectation-maximization) normalized count (native format of the 
dataset). For the correlations and survival analysis of the dataset PAAD, 
only KRAS-mutated tissue samples were considered (subset PAAD-K). 
Patients with partial or incomplete data were eliminated from the 
analysis. The patient number is reported in the related legends. For 
the division in high and low expression, the median was considered 
as threshold to discriminate between the two groups. The data used 
in the comparative analysis of ACSL3 expression in normal tissue, 
primary PDAC, and metastatic tissue were downloaded from the 
GEO, subset GSE71729, and, in the paired analysis of ACSL3 ex-
pression comparison between PDAC and healthy matched tissue, 
from the subset GSE62452. In both cases, data were expressed as 
entire numbers: in the first case normalized to one, and in the second 
by global average expression.
Statistical analysis and elaboration
Error bars represent mean ± SD or mean ± SEM (indicated in the 
figure legends). The significance of the results was determined by 
using two-tailed unpaired Student’s t test or one-way analysis of 
variance (ANOVA) when more than two groups were compared. 
Significance is indicated in the related figure legends. The in vitro 
experiments (except the two cytokine arrays that were repeated twice) 
were repeated three times. No outliers were found in any dataset, and 
no animals or data were excluded from statistical analysis. Correlations 
are expressed as R (Pearson), and fitting is done as implemented in 
GraphPad Prism v.7.00 (GraphPad Software, San Diego, CA).
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/6/44/eabb9200/DC1
View/request a protocol for this paper from Bio-protocol.
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